R13 (drug)
chemical compound
R13, also known as BrAD-R13 or as Braegen-01, is a small-molecule flavonoid and orally active, potent, and selective agonist of the tropomyosin receptor kinase B (TrkB), the main signaling receptor for the neurotrophin brain-derived neurotrophic factor (BDNF), which is under development for the potential treatment of Alzheimer's disease, amyotrophic lateral sclerosis (ALS), depressive disorders, Parkinson's disease, and schizophrenia. It is taken orally.
The drug is a structural modification and prodrug of 7,8-dihydroxyflavone (7,8-DHF; tropoflavin) with improved potency and pharmacokinetics, namely oral bioavailability and duration. The compound is a replacement for the earlier tropoflavin prodrug R7 and has similar properties to it. It was developed because while R7 displayed a good drug profile in animal studies, it showed almost no conversion into tropoflavin in human liver microsomes. In contrast to R7, R13 is readily hydrolyzed into tropoflavin in human liver microsomes.
R13, under the synonym and developmental code name BrAD-R13, is being developed by Braegen Pharmaceutical in China. As of August 2025, it is in phase 1 clinical trials for Alzheimer's disease and the preclinical research stage of development for all other indications.
The public source identifies “R13 (drug)” as chemical compound. This brief keeps that definition visible, then builds a research path around drug, chemical and compound.
Why this record matters
A short description can identify a subject without explaining its stakes. For “R13 (drug)”, the useful work is to connect “chemical compound” to the records capable of establishing context and consequence.
Stable identifiers, scientific names and standards terminology offer the best bridge between this overview and specialist evidence. The source revision retrieved here is dated Aug 16, 2026. The linked authority identifier is Q55283856. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2025.
Scientific names, classifications and consensus can change while older terminology persists in catalogues and historical literature. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “R13 (drug)”, its source revision and the description used here.
- Expand the search: follow R13 (drug) primary sources, R13 (drug) archive and drug research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “R13 (drug)”?
- Which observation, specimen, dataset or publication supports the account?
- Has classification or technical consensus changed since the cited source?
Search terms from this dossier
This entry incorporates text from “R13 (drug)” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.